Details for Patent: 8,414,921
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,414,921 protect, and when does it expire?
Patent 8,414,921 protects JANUMET and is included in one NDA.
Protection for JANUMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has nine patent family members in six countries.
Summary for Patent: 8,414,921
| Title: | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| Abstract: | Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions. |
| Inventor(s): | Kamali; Ashkan (West Conshohocken, PA), Alani; Laman (Lansdale, PA), Fliszar; Kyle A. (Quakertown, PA), Ghosh; Soumojeet (Lansdale, PA), Tijerina; Monica (Doylestown, PA) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 12/085,722 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,414,921 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; Use; Formulation; |
Drugs Protected by US Patent 8,414,921
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-002 | Mar 30, 2007 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Merck Sharp Dohme | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-001 | Mar 30, 2007 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,414,921
| PCT Information | |||
| PCT Filed | December 12, 2006 | PCT Application Number: | PCT/US2006/047380 |
| PCT Publication Date: | July 12, 2007 | PCT Publication Number: | WO2007/078726 |
International Family Members for US Patent 8,414,921
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006333151 | See Plans and Pricing | |||
| Canada | 2633167 | See Plans and Pricing | |||
| China | 101365432 | See Plans and Pricing | |||
| European Patent Office | 1962827 | See Plans and Pricing | |||
| Japan | 2009519934 | See Plans and Pricing | |||
| Japan | 2013047260 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
